Jignesh K Patel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7477059/publications.pdf

Version: 2024-02-01

98 5,221 29 70
papers citations h-index g-index

99 99 99 4947 all docs docs citations times ranked citing authors

#	Article	IF	Citations
1	The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. Journal of Heart and Lung Transplantation, 2010, 29, 914-956.	0.3	1,385
2	Report from a consensus conference on primary graft dysfunction after cardiac transplantation. Journal of Heart and Lung Transplantation, 2014, 33, 327-340.	0.3	523
3	Report from a consensus conference on antibody-mediated rejection in heart transplantation. Journal of Heart and Lung Transplantation, 2011, 30, 252-269.	0.3	328
4	Asymptomatic Antibody-mediated Rejection After Heart Transplantation Predicts Poor Outcomes. Journal of Heart and Lung Transplantation, 2009, 28, 417-422.	0.3	190
5	Transthyretin Stabilization by AG10 in Symptomatic Transthyretin AmyloidÂCardiomyopathy. Journal of the American College of Cardiology, 2019, 74, 285-295.	1.2	170
6	Ten-Year Follow-Up of a Randomized Trial of Pravastatin in Heart Transplant Patients. Journal of Heart and Lung Transplantation, 2005, 24, 1736-1740.	0.3	165
7	Report From a Consensus Conference on the Sensitized Patient Awaiting Heart Transplantation. Journal of Heart and Lung Transplantation, 2009, 28, 213-225.	0.3	158
8	Reduction of alloantibodies via proteosome inhibition in cardiac transplantation. Journal of Heart and Lung Transplantation, 2011, 30, 1320-1326.	0.3	145
9	Noninvasive detection of graft injury after heart transplant using donor-derived cell-free DNA: A prospective multicenter study. American Journal of Transplantation, 2019, 19, 2889-2899.	2.6	138
10	Predicted heart mass is the optimal metric for size match in heart transplantation. Journal of Heart and Lung Transplantation, 2019, 38, 156-165.	0.3	138
11	The management of antibodies in heart transplantation: An ISHLT consensus document. Journal of Heart and Lung Transplantation, 2018, 37, 537-547.	0.3	114
12	Increased Negative Impact of Donor HLA-Specific Together With Non-HLA–Specific Antibodies on Graft Outcome. Transplantation, 2014, 97, 595-601.	0.5	105
13	HLA and MICA: Targets of Antibody-Mediated Rejection in Heart Transplantation. Transplantation, 2011, 91, 1153-1158.	0.5	99
14	Benefit of immune monitoring in heart transplant patients using ATP production in activated lymphocytes. Journal of Heart and Lung Transplantation, 2010, 29, 504-508.	0.3	91
15	The long-term outcome of treated sensitized patients who undergo heart transplantation. Clinical Transplantation, 2011, 25, E61-E67.	0.8	91
16	Cardiac allograft rejection. Journal of the Royal College of Surgeons of Edinburgh, 2011, 9, 160-167.	0.8	84
17	Early Denervation and Later Reinnervation of the Heart Following Cardiac Transplantation: A Review. Journal of the American Heart Association, 2016, 5, .	1.6	83
18	Heart transplant recipients supported with extracorporeal membrane oxygenation: Outcomes from a single-center experience. Journal of Heart and Lung Transplantation, 2011, 30, 1250-1256.	0.3	82

#	Article	IF	CITATIONS
19	Evaluation for Heart Transplantation andÂLVAD Implantation. Journal of the American College of Cardiology, 2020, 75, 1471-1487.	1.2	77
20	Randomized Pilot Trial of Gene Expression Profiling Versus Heart Biopsy in the First Year After Heart Transplant. Circulation: Heart Failure, 2015, 8, 557-564.	1.6	74
21	Calculated panel-reactive antibody predicts outcomes on the heart transplant waiting list. Journal of Heart and Lung Transplantation, 2017, 36, 787-796.	0.3	71
22	High-Throughput Precision Phenotyping of Left Ventricular Hypertrophy With Cardiovascular Deep Learning. JAMA Cardiology, 2022, 7, 386.	3.0	63
23	Desensitization strategies in adult heart transplantation—Will persistence pay off?. Journal of Heart and Lung Transplantation, 2016, 35, 962-972.	0.3	56
24	Optimizing transplantation of sensitized heart candidates using 4 antibody detection assays to prioritize the assignment of unacceptable antigens. Journal of Heart and Lung Transplantation, 2016, 35, 165-172.	0.3	47
25	Complement inhibition for prevention of antibody-mediated rejection in immunologically high-risk heart allograft recipients. American Journal of Transplantation, 2021, 21, 2479-2488.	2.6	41
26	Association of a Novel Diagnostic Biomarker, the Plasma Cardiac Bridging Integrator 1 Score, With Heart Failure With Preserved Ejection Fraction and Cardiovascular Hospitalization. JAMA Cardiology, 2018, 3, 1206.	3.0	35
27	Combined Heart and Kidney Transplantation: Clinical Experience in 100 Consecutive Patients. Journal of the American Heart Association, 2019, 8, e010570.	1.6	33
28	Successful Treatment of Severe COVID-19 Pneumonia With Clazakizumab in a Heart Transplant Recipient: A Case Report. Transplantation Proceedings, 2020, 52, 2711-2714.	0.3	33
29	Induction Therapy With Antithymocyte Globulin in Patients Undergoing Cardiac Transplantation Is Associated With Decreased Coronary Plaque Progression as Assessed by Intravascular Ultrasound. Circulation: Heart Failure, 2016, 9, e002252.	1.6	32
30	B cells in transplantation. Journal of Heart and Lung Transplantation, 2016, 35, 704-710.	0.3	29
31	Comparative Prognostic and Diagnostic Value of Myocardial Blood Flow and Myocardial Flow Reserve After Cardiac Transplantation. Journal of Nuclear Medicine, 2020, 61, 249-255.	2.8	28
32	Simultaneous Tc-99m PYP/Tl-201 dual-isotope SPECT myocardial imaging in patients with suspected cardiac amyloidosis. Journal of Nuclear Cardiology, 2020, 27, 28-37.	1.4	25
33	Prognostic Value of Increased Mitral Valve Gradient After Transcatheter Edge-to-Edge Repair for Primary MitralÂRegurgitation. JACC: Cardiovascular Interventions, 2022, 15, 935-945.	1.1	25
34	Risk of deep vein thrombosis and pulmonary embolism after heart transplantation: clinical outcomes comparing upper extremity deep vein thrombosis and lower extremity deep vein thrombosis. Clinical Transplantation, 2015, 29, 629-635.	0.8	22
35	Mechanical circulatory support for cardiac amyloidosis. Clinical Transplantation, 2019, 33, e13663.	0.8	22
36	HLA-DQ mismatches stimulate de novo donor specific antibodies in heart transplant recipients. Human Immunology, 2020, 81, 330-336.	1,2	21

#	Article	IF	CITATIONS
37	Quantitative Assessment of Cardiac Hypermetabolism and Perfusion for Diagnosis of Cardiac Sarcoidosis. Journal of Nuclear Cardiology, 2022, 29, 86-96.	1.4	20
38	Recipient and surgical factors trigger severe primary graft dysfunction after heart transplant. Journal of Heart and Lung Transplantation, 2021, 40, 970-980.	0.3	18
39	Cardiac Amyloidosis Treatment. Methodist DeBakey Cardiovascular Journal, 2022, 18, 59-72.	0.5	18
40	Extracorporeal photopheresis in heart transplant rejection. Transfusion and Apheresis Science, 2015, 52, 167-170.	0.5	17
41	Pathology of Chronic Chagas Cardiomyopathy in the United States. American Journal of Clinical Pathology, 2016, 146, 191-198.	0.4	17
42	Heart Transplant Immunosuppression Strategies at Cedars-Sinai Medical Center. International Journal of Heart Failure, 2021, 3, 15.	0.9	15
43	Improving survival during heart transplantation: diagnosis of antibody-mediated rejection and techniques for the prevention of graft injury. Future Cardiology, 2012, 8, 623-635.	0.5	14
44	Diagnosis and Management of Chagas Cardiomyopathy in the United States. Current Cardiology Reports, 2018, 20, 131.	1.3	13
45	Coronary computed tomography–angiography quantitative plaque analysis improves detection of early cardiac allograft vasculopathy: A pilot study. American Journal of Transplantation, 2020, 20, 1375-1383.	2.6	13
46	Stem cell donor HLA typing improves CPRA in kidney allocation. American Journal of Transplantation, 2021, 21, 138-147.	2.6	13
47	Outcomes of Heart Transplantation in Cardiac Amyloidosis Patients: A Single Center Experience. Transplantation Proceedings, 2021, 53, 329-334.	0.3	13
48	Fourth BNT162b2 vaccination neutralization of omicron infection after heart transplantation. Journal of Heart and Lung Transplantation, 2022, 41, 1210-1213.	0.3	12
49	Plasma kallikrein predicts primary graft dysfunction after heart transplant. Journal of Heart and Lung Transplantation, 2021, 40, 1199-1211.	0.3	11
50	The impact of mean firstâ€year heart rate on outcomes after heart transplantation: does it make a difference?. Clinical Transplantation, 2013, 27, 659-665.	0.8	10
51	Association of vimentin antibody and other non-HLA antibodies with treated antibody mediated rejection in heart transplant recipients. Human Immunology, 2020, 81, 671-674.	1.2	10
52	Intermediateâ€term outcomes of heart transplantation for cardiac amyloidosis in the current era. Clinical Transplantation, 2021, 35, e14308.	0.8	10
53	Diagnostic Accuracy of CardiovascularÂMagnetic Resonance for Cardiac Transplant Rejection. JACC: Cardiovascular Imaging, 2021, 14, 2337-2349.	2.3	10
54	Kinetics of cellular and humoral responses to third BNT162B2 COVID-19 vaccine over six months in heart transplant recipients â€" implications for the omicron variant. Journal of Heart and Lung Transplantation, 2022, 41, 1417-1425.	0.3	10

#	Article	IF	CITATIONS
55	Quantitative myocardial tissue characterization by cardiac magnetic resonance in heart transplant patients with suspected cardiac rejection. Clinical Transplantation, 2019, 33, e13704.	0.8	9
56	Recent advances in the role of mammalian target of rapamycin inhibitors on cardiac allograft vasculopathy. Clinical Transplantation, 2020, 34, e13769.	0.8	9
57	Thoracic Organ Transplantation: Laboratory Methods. Methods in Molecular Biology, 2013, 1034, 127-143.	0.4	9
58	Cerebral Amyloid Angiopathy-Related Inflammation in the Immunosuppressed: A Case Report. Frontiers in Neurology, 2019, 10, 1283.	1.1	8
59	Statistical performance of 16 posttransplant risk scores in a contemporary cohort of heart transplant recipients. American Journal of Transplantation, 2021, 21, 645-656.	2.6	8
60	cBIN1 Score (CS) Identifies Ambulatory HFrEF Patients and Predicts Cardiovascular Events. Frontiers in Physiology, 2020, 11, 503.	1.3	7
61	JC virusâ€associated nephropathy in a postâ€heart and â€kidney transplantation patient. Transplant Infectious Disease, 2020, 22, e13288.	0.7	7
62	The effects of donorâ€specific antibody characteristics on cardiac allograft vasculopathy. Clinical Transplantation, 2021, 35, e14483.	0.8	7
63	Corticosteroid wean after heart transplantationâ€"Is there a risk for antibody formation?. Clinical Transplantation, 2017, 31, e12916.	0.8	6
64	Desensitization in heart transplant recipients: Who, when, and how. Clinical Transplantation, 2019, 33, e13639.	0.8	6
65	Amyloid and the Heart. Current Cardiology Reports, 2019, 21, 164.	1.3	6
66	Heterogeneity of liver fibrosis in patients with congestive hepatopathy: A biopsy and explant comparison series. Annals of Diagnostic Pathology, 2022, 56, 151876.	0.6	6
67	Elevated immune monitoring early after cardiac transplantation is associated with increased plaque progression by intravascular ultrasound. Clinical Transplantation, 2015, 29, 103-109.	0.8	5
68	Vitamin therapy after heart transplantation. Expert Review of Cardiovascular Therapy, 2015, 13, 1071-1074.	0.6	5
69	Elevated immune monitoring as measured by increased adenosine triphosphate production in activated lymphocytes is associated with accelerated development of cardiac allograft vasculopathy after cardiac transplantation. Journal of Heart and Lung Transplantation, 2016, 35, 1018-1023.	0.3	5
70	The \hat{I}^2 1 -Adrenergic Receptor IgG Subclass 3 Autoantibody in DilatedÂCardiomyopathy. Journal of the American College of Cardiology, 2017, 69, 978-980.	1.2	5
71	Donor organ evaluation in the era of coronavirus disease 2019: A case of nosocomial infection. Journal of Heart and Lung Transplantation, 2020, 39, 611-612.	0.3	5
72	Crossing low/moderateâ€level donorâ€specific antibodies during heart transplantation. Clinical Transplantation, 2021, 35, e14196.	0.8	5

#	Article	IF	CITATIONS
73	The impact of induction therapy on mortality and treated rejection in cardiac transplantation: A retrospective study. Journal of Heart and Lung Transplantation, 2022, , .	0.3	5
74	Clinical Utility of SPECT in the Heart Transplant Population. Transplantation, 2021, Publish Ahead of Print, .	0.5	4
75	Eculizumab for antibodyâ€mediated rejection in heart transplantation: A caseâ€control study. Clinical Transplantation, 2021, , e14454.	0.8	4
76	Development and validation of specific post-transplant risk scores according to the circulatory support status at transplant: A UNOS cohort analysis. Journal of Heart and Lung Transplantation, 2021, 40, 1235-1246.	0.3	4
77	Post-transplantation outcomes of sensitized patients receiving durable mechanical circulatory support. Journal of Heart and Lung Transplantation, 2022, 41, 365-372.	0.3	4
78	Heart transplant in Jehovah's Witness patients: A case-control study. Journal of Heart and Lung Transplantation, 2021, 40, 575-579.	0.3	3
79	Blood-based immunological monitoring after heart transplant. Current status and future prospects. Indian Journal of Thoracic and Cardiovascular Surgery, 2020, 36, 194-199.	0.2	2
80	Longâ€term outcomes after heart transplantation using ex vivo allograft perfusion in standard risk donors: A singleâ€center experience. Clinical Transplantation, 2022, , e14591.	0.8	2
81	HLA Homozygosity and Likelihood of Sensitization in Kidney Transplant Candidates. Transplantation Direct, 2022, 8, e1312.	0.8	2
82	Quest for lower immunosuppression in cardiac transplantation: an analysis of the TICTAC trial. Future Cardiology, 2011, 7, 293-297.	0.5	1
83	Early and late AMR in heart transplantationâ€"Distinct entities?. Journal of Heart and Lung Transplantation, 2016, 35, 1055-1056.	0.3	1
84	Neurological Prognostication of Cardiac Arrest in an Era of Extracorporeal Membrane Oxygenation. Neurohospitalist, The, 2017, 7, 35-38.	0.3	1
85	Prioritization for sensitization in heart transplantation—An approach toward greater equity. Journal of Heart and Lung Transplantation, 2017, 36, 486-487.	0.3	1
86	The rising scourge of acute renal injury after heart transplantation. Transplant International, 2020, 33, 1643-1644.	0.8	1
87	Seeing Old Landscapes With New Eyes: A Voyage Into the Endomyocardial Biopsy to Improve Risk Stratification After Heart Transplant Using Computational Analysis. Circulation, 2022, 145, 1578-1580.	1.6	1
88	Approach to the Sensitized Patient Awaiting Heart Transplantation. Current Transplantation Reports, 2014, 1, 290-299.	0.9	0
89	Response. Transplantation Proceedings, 2015, 47, 2077.	0.3	0
90	The Sensitized Patient Awaiting Heart Transplantation. , 2017, , 57-71.		0

#	Article	lF	CITATIONS
91	Peri-operative desensitizationâ€"A promising strategy for overcoming the antibody barrier in heart transplantation. Journal of Heart and Lung Transplantation, 2018, 37, 577-578.	0.3	O
92	Response by Coutance et al to Letter Regarding Article, "ldentification and Characterization of Trajectories of Cardiac Allograft Vasculopathy After Heart Transplantation: A Population-Based Studyâ€, Circulation, 2020, 142, e409-e410.	1.6	0
93	Left ventricular assist systems and strokes: Statins to the rescue?. Journal of Heart and Lung Transplantation, 2020, 39, 593-594.	0.3	O
94	The challenge of heart transplantation in sensitized patientsâ€"carfilzomib and the importance of shared experience. Journal of Heart and Lung Transplantation, 2021, 40, 604-606.	0.3	0
95	Advanced heart failure and heart transplantation in adult congenital heart disease in the current era. Clinical Transplantation, 2021, 35, e14451.	0.8	O
96	Heart transplantation in muscular dystrophy: Singleâ€eenter analysis. Clinical Transplantation, 2022, , e14645.	0.8	0
97	Cardiac microstructural alterations in immune-inflammatory myocardial disease: a retrospective case-control study. Cardiovascular Ultrasound, 2022, 20, 9.	0.5	0
98	Induction Therapy and Therapeutic Antibodies. Handbook of Experimental Pharmacology, 2022, , .	0.9	0